as 05-30-2025 4:00pm EST
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
Founded: | 2014 | Country: | United States |
Employees: | N/A | City: | NEW YORK |
Market Cap: | 20.6M | IPO Year: | 2017 |
Target Price: | $2.78 | AVG Volume (30 days): | 441.7K |
Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.34 | EPS Growth: | N/A |
52 Week Low/High: | $0.24 - $3.31 | Next Earning Date: | 05-13-2025 |
Revenue: | $548,000 | Revenue Growth: | 15.61% |
Revenue Growth (this year): | -56.39% | Revenue Growth (next year): | 21.49% |
OVID Breaking Stock News: Dive into OVID Ticker-Specific Updates for Smart Investing
Zacks
19 days ago
GlobeNewswire
19 days ago
Zacks
a month ago
GlobeNewswire
2 months ago
Simply Wall St.
3 months ago
MT Newswires
3 months ago
Zacks
3 months ago
GlobeNewswire
3 months ago
The information presented on this page, "OVID Ovid Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.